Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.
Ontology highlight
ABSTRACT: Mesothelin is a cell surface protein that is overexpressed in numerous cancers, including breast, ovarian, lung, liver, and pancreatic tumors. Aberrant expression of mesothelin has been shown to promote tumor progression and metastasis through interaction with established tumor biomarker CA125. Therefore, molecules that specifically bind to mesothelin have potential therapeutic and diagnostic applications. However, no mesothelin-targeting molecules are currently approved for routine clinical use. While antibodies that target mesothelin are in development, some clinical applications may require a targeting molecule with an alternative protein fold. For example, non-antibody proteins are more suitable for molecular imaging and may facilitate diverse chemical conjugation strategies to create
SUBMITTER: Sirois AR
PROVIDER: S-EPMC5940182 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
ACCESS DATA